These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32969164)

  • 1. Fc-Binding Antibody-Recruiting Molecules Targeting Prostate-Specific Membrane Antigen: Defucosylation of Antibody for Efficacy Improvement*.
    Sasaki K; Harada M; Yoshikawa T; Tagawa H; Harada Y; Yonemitsu Y; Ryujin T; Kishimura A; Mori T; Katayama Y
    Chembiochem; 2021 Feb; 22(3):496-500. PubMed ID: 32969164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses.
    Sasaki K; Harada M; Miyashita Y; Tagawa H; Kishimura A; Mori T; Katayama Y
    Chem Sci; 2020 Feb; 11(12):3208-3214. PubMed ID: 34122826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
    Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
    Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of a monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy.
    Sasaki K; Muguruma K; Osawa R; Fukuda A; Taniguchi A; Kishimura A; Hayashi Y; Mori T; Katayama Y
    RSC Med Chem; 2021 Mar; 12(3):406-409. PubMed ID: 34046623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
    Sustmann C; Dickopf S; Regula JT; Kettenberger H; Mølhøj M; Gassner C; Weininger D; Fenn S; Manigold T; Kling L; Künkele KP; Schwaiger M; Bossenmaier B; Griese JJ; Hopfner KP; Graff-Meyer A; Stahlberg H; Ringler P; Lauer ME; Brinkmann U; Schaefer W; Klein C
    MAbs; 2019; 11(8):1402-1414. PubMed ID: 31526159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Natural Killer Cell Immunotherapy by Rationally Assembling Fc Fragments of Antibodies onto Tumor Membranes.
    Ji T; Lang J; Ning B; Qi F; Wang H; Zhang Y; Zhao R; Yang X; Zhang L; Li W; Shi X; Qin Z; Zhao Y; Nie G
    Adv Mater; 2019 Feb; 31(6):e1804395. PubMed ID: 30549110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemically synthesized molecules with the targeting and effector functions of antibodies.
    McEnaney PJ; Fitzgerald KJ; Zhang AX; Douglass EF; Shan W; Balog A; Kolesnikova MD; Spiegel DA
    J Am Chem Soc; 2014 Dec; 136(52):18034-43. PubMed ID: 25514603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.